In context
KPV is the tripeptide lysine-proline-valine. Original studies examined intestinal transport, inflammatory signalling and experimental colitis, including a hydrogel delivery system in rats. [1–2]
At a glance
- Type
- Peptide / related experimental research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Cell and animal colitis models can explore mechanisms but do not demonstrate clinical control of inflammatory bowel disease in humans.
How to interpret this evidence
Cell and animal colitis models can explore mechanisms but do not demonstrate clinical control of inflammatory bowel disease in humans. [1] [2]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. pubmed.ncbi.nlm.nih.gov
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. pubmed.ncbi.nlm.nih.gov